Health

Anupam Mittal (Shark Tank) Cautions on Fitness Shortcuts: 'Ozempic for Weight Loss Could Become Like Eno If...'

Written by Shotlee Editorial TeamHealth Research & Writing

·December 16, 2025·1 min read

Anupam Mittal raised concerns about the potential overuse of drugs like Ozempic for weight loss. He also highlighted the upcoming expiration of key GLP-1 drug patents, possibly leading to market changes.

Anupam Mittal Cautions Against Weight Loss Shortcuts

Mittal indicated that the drug, currently priced around ₹8,800 monthly in India, might generate an annual market nearing ₹1,000 crore, according to industry projections.

Mittal also emphasized a significant shift expected in the pharmaceutical industry. The expiration of crucial GLP-1 drug patents, starting in March 2026, could pave the way for cheaper alternatives from Indian pharmaceutical firms. This, he proposed, might spark quick industry growth, potentially increasing the weight-loss drug market substantially in the years ahead. Companies like Cipla, he observed, seem suitably prepared for entering this market. Health tracking apps like Shotlee can help monitor health changes, but are not a substitute for healthy lifestyle choices.

Source Information

Originally published by mint.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: weight loss

All weight loss articles →

Wellness & Health

New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It

New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.

8 min read

More in Health

Health

New Year, New Scam: Fraudsters Target Dieters with Bogus Weight Loss Drugs

As weight loss becomes a popular New Year's resolution, many are turning to GLP-1 medications. However, scammers are leveraging fake websites and offers to steal money and personal data. The Better Business Bureau warns of fraudulent schemes targeting those seeking weight loss solutions.

2 min read

Health

GLP-1 Weight Loss Surge Fueled by Urban Affluent; Distribution and Cost Adjustments Could Alter Trajectory

Urban elites are currently the main drivers behind the increasing popularity of GLP-1 weight loss medications. Changes in distribution strategies and price adjustments could potentially transform this trend. These factors could democratize access to these treatments.

1 min read

Health

Ozempic's Impact on American Food Purchasing Habits

New research reveals that medications like Ozempic are associated with considerable decreases in household food expenditures, both in grocery stores and restaurants. The study highlights how the adoption of GLP-1 drugs impacts daily food purchasing in real-world scenarios, showing a notable shift in consumer behavior.

4 min read